［1］Zuo TT，Zheng RS，Zeng HM，et al.Incidence and trend analysis of esophageal cancer in China［J］.Chin J Oncol，2016，38(9)：703-708.［左婷婷，郑荣寿，曾红梅，等.中国食管癌发病状况与趋势分析［J］.中华肿瘤杂志，2016，38(9)：703-708.］
［2］Zhang SW，Zheng RS，Zuo TT，et al.Mortality and survival analysis of esophageal cancer in China［J］.Chin J Oncol，2016，38(9)：709-715.［张思维，郑荣寿，左婷婷，等.中国食管癌死亡状况和生存分析［J］.中华肿瘤杂志，2016，38(9)：709-715.］
［3］Zhou ZG，Gao XS，Qiao XY，et al.Literature analysis of radiotherapy for esophageal cancer in China［J］.Chin J Cancer，2010，29(10)：873-881.
［4］Ji YH，Yang XY，Wu JQ，et al.Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells［J］.Eur Rev Med Pharmacol Sci，2015，19(4)：586-591.
［5］Chen J，Ma L，Qu BL，et al.Nimotuzumab and cetuximab enhanced radiation effects on human esophageal carcinoma cells［J］.Chin J Radiol Med Prot，2014，34(7)：489-492.［陈静，马林，曲宝林，等.尼妥珠单抗及西妥昔单抗增强照射对人食管癌细胞系的作用［J］.中华放射医学与防护杂志，2014，34(7)：489-492.］
［6］Ramakrishnan MS，Eswaraiah A，Crombet T，et al.Nimotuzumab，a promising therapeutic monoclonal for treatment of tumors of epithelial origin［J］.MAbs，2009，1(1)：41-48.
［7］Diaz MA，Blanco R，Garcia B，et al.Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities［J］.Hybridoma (Larchmt)，2007，26(6)：423-431.
［8］Song H，Pan B，Yi J，et al.Featured article：Autophagic activation with nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma［J］.Exp Biol Med (Maywood)，2014，239(5)：529-541.
［9］Crombet-Ramos T，Rak J，Pérez R，et al.Antiproliferative，antiangiogenic and proapoptotic activity of h-R3：A humanized anti-EGFR antibody［J］.Int J Cancer，2002，101(6)：567-575.
［10］Zhao L，Li QQ，Zhang R，et al.The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin［J］.Tumour Biol，2012，33(4)：1115-1123.
［11］Ramos-Suzarte M，Lorenzo-Luaces P，Lazo NG，et al.Treatment of malignant，non-resectable，epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy［J］.Cancer Biol Ther，2012，13(8)：600-605.
［12］Castro G，Skare NG，Andrade CJC，et al.Chemoradiation with or without nimotuzumab in locally advanced esophageal cancer (LAEC)：A randomized phase II study (NICE trial)［J］.J Clin Oncol，2014，32(5suppl)：abstr 4078.
［13］Lai X，Gu Q，Zheng X，et al.Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma：A retrospective study［J］.J Cancer Res Ther，2016，12(Suppl)：89-95.
［14］Huang DD，Li T，Zhang J，et al.Mass screening for the short-term effects of nimotuzumab combined with synchronal radiochemotherapy in the treatment of locally advanced esophageal carcinoma［J］.Chin J Clin Oncol，2012，39(23)：1961-1963.［黄丹丹，李涛，张军，等.尼妥珠单抗联合同步放化疗治疗局部晚期食管癌的近期疗效分析［J］.中国肿瘤临床，2012，39(23)：1961-1963.］
［15］Song YP，Ma JB，Chen EC，et al.Nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced esophageal carcinoma［J］.Cancer Res Clinic，2012，24(10)：704-706.［宋轶鹏，马金波，陈尔成，等.尼妥珠单抗联合同期放化疗治疗局部进展期食管癌疗效观察［J］.肿瘤研究与临床，2012，24(10)：704-706.］
［16］Wu Churong，Yang Wen，Tang Wubin，et al.A pilot study for the effect of nimotuzumab combined with 3D-CRT and chemoradiotherapy on esophagus cancer［J］.Modern Oncology，2014，22(12)：2842-2845.［伍楚蓉，杨文，唐武兵，等.尼妥珠单抗联合三维适形放化疗治疗食管癌的初步研究［J］.现代肿瘤医学，2014，22(12)：2842-2845.］
［17］Sun CJ，Chen Y.The clinical research nimotuzumab combined with radiotherapy and chemotherapy for advanced esophageal cancer［J］.J Clin Med Liter，2014，1(13)：2346-2348.［孙长江，陈勇.放化疗联合尼妥珠单抗治疗中晚期食管癌的临床研究［J］.临床医药文献电子杂志，2014，1(13)：2346-2348.］
［18］Luo Haitao，Liang Caixia.Effect of intensity-modulated radiotherapy combined with docetaxel and nimotuzumab in treatment of patients with esophageal carcinoma［J］.Modern Oncology，2015，23(2)：219-222.［罗海涛，梁彩霞.调强放疗联合多西他赛和尼妥珠单抗治疗食管癌的疗效观察［J］.现代肿瘤医学，2015，23(2)：219-222.］
［19］Liu Huijuan，Che Yu，Liu Jia.Short term efficacy of Nimotuzumab with concurrent radiotherapy and chemotherapy for advanced esophageal cancer［J］.Modern Oncology，2015，23(18)：2587-2590.［刘慧娟，车宇，刘佳.尼妥珠单抗联合同步放、化疗治疗中晚期食管癌的近期疗效观察［J］.现代肿瘤医学，2015，23(18)：2587-2590.］
［20］Fei LS，Meng LX，Zhang GF，et al.Short-term effect of nimotuzumab combined with synchronal radiochemotherapy in treating locally advanced esophageal carcinoma［J］.Chin Med，2016，11(6)：844-847.［费立升，孟令新，张桂芳，等.尼妥珠单抗联合同步放化疗治疗局部晚期食管癌的近期效果分析［J］.中国医药，2016，11(6)：844-847.］
［21］Chen YL，Li SP，Lian YN.Clinical study on nimotuzumab combined with nadaplatin concurrent chemoradiotherapy for local advanced esophageal carcinoma［J］.J North Phar，2016，13(9)：140-141.［陈玉兰，李曙平，练英妮.尼妥珠单抗联合奈达铂同步放化疗治疗局部晚期食管癌的临床研究［J］.北方药学，2016，13(9)：140-141.］
［22］Wang L，Liang J，Li N，et al.Evaluation of nimotuzumab combined with radiotherapy on esophageal carcinoma：A phase II clinical trial［J］.J Clin Oncol，2011，29(suppl)：abstr e14637.
［23］Chen ZM，Xue Q，Chen XY，et al.Short-term efficacy and toxicity of nimotuzumab combined with simultaneous integrated boost intensity-modulated radiotherapy for locally advanced esophageal cancer［J］.Natl Med J China，2016，96(8)：640-642.［陈志明，薛强，陈晓珏，等.同步加量调强放疗联合尼妥珠单抗治疗局部晚期食管癌［J］.中华医学杂志，2016，96(8)：640-642.］
［24］Ma NY，Cai XW，Fu XL，et al.Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus［J］.Int J Clin Oncol，2014，19(2)：297-302.
［25］Lan YL，Feng CL，Cai BN，et al.Initial clinical outcome in patients with esophageal cancer after radiotherapy combined with nimotuzumab［J］.Acad J Chin PLA Med Sch，2013，34(10)：1013-1015，1035.［蓝玉玲，冯林春，蔡博宁，等.放疗同步联合尼妥珠单抗靶向治疗食管癌的初步临床观察［J］.解放军医学院学报，2013，34(10)：1013-1015，1035.］
［26］Shi YR，Wang H，Yang JR，et al.Clinical study on late course accelerated hyperfractionated intensity modulated radiation therapy plus nimotuzumab for esophageal carcinoma［J］.Cancer Res Clinic，2014，26(8)：514-517，522.［师颖瑞，王晖，杨敬儒，等.食管癌后程加速超分割调强适形放疗及联用尼妥珠单抗的研究［J］.肿瘤研究与临床，2014，26(8)：514-517，522.］
［27］Rao CY，Zhang C，Yang L，et al.Phase Ⅱ study of nimotuzumab plus 3D-CRT for local advanced esophageal cancer［J］.Zhejiang Medical Journal，2014，36(11)：1015-1018.［饶创宙，张琛，杨璐，等.尼妥珠单抗联合三维适形放疗治疗局部晚期食管癌的Ⅱ期临床研究［J］.浙江医学，2014，36(11)：1015-1018.］
［28］Wang CY，Cheng M，Yu ZR，et al.The effect of nimotuzumab combined with 3D-CRT in recurrent esophageal cancer after definitive radiotherapy［J］.Chin Remedies Clinics，2013，13(4)：504-505.［王春英，程明，于正荣，等.尼妥珠单抗联合三维适形放疗治疗根治性放疗后复发食管癌的疗效分析［J］.中国药物与临床，2013，13(4)：504-505.］
［29］Guo JH，Chen MQ，Chen C，et al.Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma［J］.Mol Clin Oncol，2015，3(5)：1135-1138.
［30］Belkhiri A，El-Rifai W.Advances in targeted therapies and new promising targets in esophageal cancer［J］.Oncotarget，2015，6(3)：1348-1358.
［31］Lledo G，Huguet F，Chibaudel B，et al.Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer：The GERCOR phase II trial ERaFOX［J］.Eur J Cancer，2016，56：115-121.
［32］Crosby T，Hurt CN，Falk S，et al.Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1)：A multicentre，phase 2/3 randomised trial［J］.Lancet Oncol，2013，14(7)：627-637.